4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid

• ChemBase编号: 1386
• 分子式: C21H15N3O4
• 平均质量: 373.3615
• 单一同位素质量: 373.10625598
• SMILES: n1c(nn(c1c1ccccc1O)c1ccc(cc1)C(=O)O)c1ccccc1O
• Canonical SMILES: OC(=O)c1ccc(cc1)n1nc(nc1c1ccccc1O)c1ccccc1O
• InChI: InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
• InChIKey: BOFQWVMAQOTZIW-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
• IUPAC传统名: deferasirox; exjade
• 商标名: Exjade
• 别名: 4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic Acid; Deferasiroxum [inn-latin]; deferasirox; ICL 670; Deferasirox; Exjade; ICL-670; ICL-670A; CGP-72670

登记号

• CAS号: 201530-41-8
• PubChem SID: 46506791; 160964846
• PubChem CID: 5493381

理论计算性质

JChem

• Acid pKa: 4.548632
• 质子受体: 6
• 质子供体: 3
• LogD (pH = 5.5): 3.7476976
• LogD (pH = 7.4): 1.9242212
• Log P: 4.744616
• 摩尔折射率: 125.3245 cm^3
• 极化性: 40.60579 Å^3
• 极化表面积: 108.47 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 4.01
• LOG S: -4.04
• 溶解度: 3.43e-02 g/l

分子性质

理化性质

• 溶解度: 0.038 mg/mL at 37 oC [YALKOWSKY,SH & DANNENFELSER,RM (1992)]; DMSO; MeOH
• 外观: White to Off-White Solid
• 熔点: 260-262°C
• 疏水性(logP): 3.52 [HANSCH,C ET AL. (1995)]

安全信息

• 保存条件: -20°C; -20°C Freezer

产品相关信息

• 成盐信息: Free Base

详细说明

DrugBank - DB01609

• Drug Groups: approved; investigational
• Description: Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose.
• Indication: For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
• Pharmacology: Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. CYP450-catalyzed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion.
• Absorption: The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
• Half Life: The mean elimination half-life ranged from 8 to 16 hours following oral administration.
• Protein Binding: Deferasirox is highly (~99%) protein bound almost exclusively to serum albumin.
• Elimination: Deferasirox and metabolites are primarily (84% of the dose) excreted in the feces.; Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose).
• Distribution: * 14.37 ± 2.69 L
• External Links: Wikipedia; RxList; Drugs.com

Selleck Chemicals - S1712

Research Area: Cardiovascular Disease
Biological Activity:
Deferasirox(Exjade) is a rationally-designed oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. [1]

Toronto Research Chemicals - D228650

Orally active tridentate iron chelator.

参考文献

• http://en.wikipedia.org/wiki/Deferasirox
• Hershko, C., et al.: Blood, 97, 1115 (2001)
• Galanello, R., et al.: J. Clin. Pharmacol., 43, 565 (2001)
• Nick, H., et al.: Curr. Med. Chem., 10, 1065 (2001)